Discovery Of Glycoprotein Biomarkers Using NuGel™ Glycoprotein Enrichment Phenyl Boronic Acid (PBA) Kit.
Providing unrivalled specificity, NuGel™ Glycoprotein Enrichment PBA Kit contains phenyl boronic acid which covalently reacts with 1,2-cis-diol group–containing molecules. This unique chemistry eliminates the requirement for forming complex saccharide recognition motifs for interaction. The PBA ligand binds to the 1,2-cis-diol groups of biomolecules and enriches for heterogeneous sets of glycoproteins containing both N-linked and O-linked oligosaccharides. The specialized heterogenous nature of NuGel™ Glycoprotein Enrichment PBA Kit’s organo-boronic acid groups makes it applicable to all kinds of glycopeptides regardless of the sizes, structures, and hydrophilicities. The boronic acids facilitate the capturing of heterogeneous groups of O-linked oligosaccharides.
NuGel™ Glycoprotein Enrichment PBA Kit provides good reproducibility, simple protocol, and high-throughput capability. For detailed structural characterization of low-abundance glycoproteins, NuGel™ Glycoprotein Enrichment PBA Kit enriches glycoproteins from blood, serum, plasma, tissue or cell culture media. Glycoprotein isolation and enrichment might lead to biomarkers eg: biomarkers may be glycoproteins present in only minute quantities in tissue extracts and physiological fluids.
Examples Of Hetergenous Glycoproteins Enriched From Four Different Mammalian Samples
Properties of NuGel™ Glycoprotein Enrichment PBA Kit
- Cis-diol specific, enriches heterogeneous sets of glycoproteins
- Unmasks glycoproteins from high abundance proteins, most notably albumin
- Disposable, easy spin filter format, no cross-contamination
- Efficient new surface technology ideal for proteomic applications
- Enriches glycoproteins from blood, serum, plasma, tissue or cell culture media.
- Removes > 90% of serum albumin (the non-glycosylated fraction)
- Sorbitol elution at pH 7.5 – 8.5
1. Comunale MA, Lowman M, Long RE, Krakover J, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res.2006;5:308–15.
2. An HJ, Miyamoto S, Lancaster KS, Kirmiz C, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res. 2006;5:1626–35.
3. Dai Z, Liu YK, Cui JF, Shen HL, et al. Identification and analysis of altered alpha1,6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics. 2006;6:5857–67.
4. Zhao J, Simeone DM, Heidt D, Anderson MA, et al. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. J Proteome Res. 2006;5:1792–802.
5. Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D. T., Loo J. A. (2006) Identification ofN-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry. J. Proteome Res. 5, 1493–1503
6. Aoyagi Y. Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconj J. 1995;12:194–9.
7. Yamashita K, Koide N, Endo T, Iwaki Y, et al. Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma. J Biol Chem. 1989;264:2415–23.